New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst
A report released today by BioBeat showcasing the 30 top female leaders in the UK bioscience sector has named three people from organisations based at Stevenage Bioscience Catalyst (SBC), totalling 10% of the list.
This is the seventh annual Movers and Shakers report released by BioBeat, and this year highlighted individuals pioneering scientists, financial experts, collaborators, innovators focused on impact on patients’ lives, and infrastructure specialists. This year’s Movers and Shakers also features alumni from previous reports, in which SBC is strongly represented, including CEO Dr Sally Ann Forsyth.
Shree Patel, Senior Vice President Global Clinical Operations at Achilles Therapeutics, said “I’m truly honoured to be included in this year’s Movers and Shakers report, and especially alongside so many pioneering women in our sector”.
Nicole Mathon, Associate Director, Opportunity Assessment Group at LifeArc, said “The BioBeat Movers and Shakers report is always filled with such exceptional talent and I’m thrilled to be included in it”.
Bakul Gupta, Co-Founder at ImmTune Therapies, said “As a new occupier at Stevenage Bioscience Catalyst, I am both elated to be mentioned in the BioBeat Movers and Shakers report this year, and looking forward to working alongside so many other talented women in the sector”.
Dr Sally Ann Forsyth, CEO at SBC, commented “I am delighted that so many of our occupiers are included in the BioBeat report, and want to congratulate the winners on joining our long list of historic Movers and Shakers at SBC”.
Stevenage Bioscience Catalyst is a world-leading science park of global significance and home to the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, occupier companies have secured £1.6bn in funding and it has attracted over 40 high-profile occupier businesses and world-class research organisations to Stevenage. This includes the Cell and Gene Therapy Catapult Manufacturing Centre which is currently undergoing expansion to help support up to 12 cell and gene therapy companies.
About Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell.
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients. The charity is pioneering new ways to turn great science into greater patient impact. It has dedicated laboratories in Stevenage where around 80 scientists work on antibody and small molecule projects, while the Edinburgh lab progresses diagnostics development.
About ImmTune Therapies
ImmTune Therapies is developing gene delivery vectors for specific modification of immune cells inside a patient’s body. Their ambition is to enable an in vivo cell therapy process, whereby an injection of their product generates a dose of therapeutic cells, such as CAR-Ts, within the body.
BioBeat connects entrepreneurs with leaders in bioscience, by working to respond to challenges and open opportunities through the inspirational experience of women leaders. Miranda Weston-Smith founded BioBeat to bring fresh energy and insights for a healthier world.
BioBeat has produced the Movers & Shakers in BioBusiness report every year since 2014, identifying outstanding female leadership talent in UK bioscience. The annual BioBeat summit brings together pioneers in biotech to nurture innovation and forge new partnerships.
Find out more at www.mws-consulting.co.uk/biobeat/